KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Operating Leases: 2019-2024

Historic Operating Leases for Xenon Pharmaceuticals (XENE) over the last 6 years, with Dec 2024 value amounting to $7.6 million.

  • Xenon Pharmaceuticals' Operating Leases fell 18.66% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 18.66%. This contributed to the annual value of $7.6 million for FY2024, which is 20.39% down from last year.
  • As of FY2024, Xenon Pharmaceuticals' Operating Leases stood at $7.6 million, which was down 20.39% from $9.6 million recorded in FY2023.
  • Xenon Pharmaceuticals' 5-year Operating Leases high stood at $9.9 million for FY2022, and its period low was $3.0 million during FY2020.
  • In the last 3 years, Xenon Pharmaceuticals' Operating Leases had a median value of $9.6 million in 2023 and averaged $9.1 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Operating Leases soared by 310.50% in 2020, and later decreased by 20.39% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Operating Leases (Yearly) stood at $3.0 million in 2020, then surged by 150.89% to $7.7 million in 2021, then climbed by 29.99% to $9.9 million in 2022, then dropped by 3.45% to $9.6 million in 2023, then dropped by 20.39% to $7.6 million in 2024.